Foghorn Therapeutics — Third Quarter 2026 Earnings Summary

Foghorn Therapeutics reported a net income of $58.2 million for the third quarter of 2026, driven by $83.5 million in collaboration revenue and a reduction in operating expenses. The company maintains a strong balance sheet with $156.2 million in cash and marketable securities, providing a runway into the second half of 2029. Key pipeline updates include advancing a novel oral small molecule for inflammatory bowel disease with potential first-in-human trials by the end of 2027 and targeting an IND filing for a selective EP300 degrader in 2027. Additionally, the company is developing an induced-proximity approach to degrade secreted and transmembrane proteins across oncology and immunology indications.